OSE Immunotherapeutics was one of the biggest risers on the Paris Bourse on Tuesday, after the biotech company announced positive initial clinical results for its new monoclonal antibody.

These initial results - presented at the ESMO conference - show that adverse events occurring during the treatment period are manageable, while the maximum tolerated dose was not reached.

These data were unveiled by Boehringer Ingelheim - OSE's partner - which is currently evaluating BI 770371 in a Phase 1 clinical trial conducted in Canada, the USA and Japan in patients with solid tumors.

Boehringer Ingelheim is also evaluating BI 765063, another OSE compound, in various combinations in patients with squamous cell carcinoma of the head and neck, or metastatic or recurrent hepatocellular carcinoma, in a Phase 1b trial in the USA, Europe and Asia.

OSE Immunotherapeutics shares gained 1.7% to 9.45 euros at 10:15 a.m., after reaching as high as 4.3%, the biggest gain on the SBF 120 index, which lost 1.21% at the same time

Copyright (c) 2023 CercleFinance.com. All rights reserved.